Rapport Therapeutics, Inc. Common Stock (RAPP) - Total Liabilities
Based on the latest financial reports, Rapport Therapeutics, Inc. Common Stock (RAPP) has total liabilities worth $36.06 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check RAPP asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Rapport Therapeutics, Inc. Common Stock - Total Liabilities Trend (2022–2025)
This chart illustrates how Rapport Therapeutics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of Rapport Therapeutics, Inc. Common Stock.
Rapport Therapeutics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Rapport Therapeutics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
NRW Holdings Limited
F:3NR
|
Germany | €1.09 Billion |
|
Sai Gon Ha Noi Commercial Joint Stock Bank
VN:SHB
|
Vietnam | ₫859.26 Trillion |
|
Signify N.V.
AS:LIGHT
|
Netherlands | €3.95 Billion |
|
Perdoceo Education Corp
NASDAQ:PRDO
|
USA | $301.53 Million |
|
Sunstone Hotel Investors Inc
NYSE:SHO
|
USA | $1.15 Billion |
|
UFP Technologies Inc
NASDAQ:UFPT
|
USA | $248.91 Million |
|
Shenzhen Overseas Chinese Town Co Ltd
SHE:000069
|
China | CN¥211.29 Billion |
|
Select Medical Holdings
NYSE:SEM
|
USA | $3.94 Billion |
Liability Composition Analysis (2022–2025)
This chart breaks down Rapport Therapeutics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Rapport Therapeutics, Inc. Common Stock to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 15.72 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Rapport Therapeutics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Rapport Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual total liabilities of Rapport Therapeutics, Inc. Common Stock from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $27.78 Million | +192.22% |
| 2024-12-31 | $9.51 Million | -94.75% |
| 2023-12-31 | $181.06 Million | +1396.59% |
| 2022-12-31 | $12.10 Million | -- |
About Rapport Therapeutics, Inc. Common Stock
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containin… Read more